Scientific organizations recently called for a 10-year ban on human germline editing. But will we ever be ready? And how ...

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

Japanese researchers have successfully eliminated the extra chromosome responsible for Down syndrome using CRISPR gene ...

Quantum-Si Customer to Showcase Protein Barcoding for Nucleic Acid–LNP Therapeutic Development at Festival of Genomics Boston ...

Back in 1900 the life expectancy of people with Down Syndrome was 9 years. In 1984, it was 28 years, today it's leveled off between 50 and 60 ...

CRISPR Therapeutics’ CRSP first marketed product is the one-shot gene therapy Casgevy, approved in late 2023 and early 2024 ...